No cut in French health spend, says Sarkozy

8 April 2007

French presidential candidate Nicolas Sarkozy, having launched his campaign on the health policy front with a call for the introduction of a regime of patient charges, has now followed this markedly unpopular policy with a bold declaration on health spending.

Mr Sarkozy, referring to his own boldness, has said it was "quite something" to advocate patient charge regimes when his political presidential rivals have stayed quiet on the health financing issue. However, he said, it was essential to make clear that "it will not be possible to reduce health spending" while at the same time the courage is needed to make equally clear that state support cannot simply go on rising.

Mr Sarkozy is proposing four separate regimes under which health fund patients will not be reimbursed for "the first few euros" of the cost of drugs, consultations, biological analysis and hospital expenses. These would replace the current system of charges of 1 euro ($1.34) per medical consultation and 18 euros for major acts of treatment. He added that the level of the proposed charges would rise proportionally if the health fund system was in overall deficit.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight